Systematic Review of the Effectiveness of Pharmacological Interventions in the Treatment of Spasticity of the Hemiparetic Lower Extremity More Than Six Months Post Stroke

REFERENCES

• Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, eds. Spasticity: Disordered Motor Control. Miami, FL: Year Book Medical Publishers; 1980:485–494.
   Google Scholar
• Sommerfeld DK, Gripestedt U, Weimer AK. Spasticity after stroke: an overview of prevalence, test instruments, and treatments. Am I Phys Med Rehabil. 2010;91:814–820.
   Web of Science ®Google Scholar
• Lundstrom E, Terent A, Borg J. Prevalence of disabling spasticity 1 year after first-ever stroke. Eur I Neurol. 2008;15:533–539.
   PubMed Web of Science ®Google Scholar
• Ward AB. A literature review of the pathophysiology and onset of post-stroke spasticity. Eur I Neurol. 2012;19:21–27.
   PubMed Web of Science ®Google Scholar
• Bhakta BB. Management of spasticity in stroke. Br Med Bull. 2000;56:476–485.
   PubMed Web of Science ®Google Scholar
• de Haart M, Geurts AC, Huidekoper SC, Fasotti L, van Limbeek J. Recovery of standing balance in post-acute stroke patients: a rehabilitation cohort study. Arch Phys Med Rehabil. 2004;85:886–895.
   PubMed Web of Science ®Google Scholar
• Bobath B. Adult Hemiplegia: Evaluation and Treatment. 3rd ed. London: MPG Books Ltd; 1990.
   Google Scholar
• Bogataj U, Gros N, Kljajic M, Acimovic R, Malezic M. Rehabilitation of gait in patients with hemiplegia. A comparison between conventional therapy and multichannel functional stimulation therapy. Phys Ther. 1995;75:490–502.
   PubMed Web of Science ®Google Scholar
• Albright AL. Neurosurgical treatment of spasticity and other pediatric movement disorders. I Child Neurol 2003;18:S67–78.
   Google Scholar
• Bakke F. The acute treatment of stroke. In: Harrison MA, Rustad RA, eds. Physiotherapy in Stroke Management. Edinburgh, UK: Churchill Livingstone; 1995:215–222.
   Google Scholar
• Johnson CA, Burridge JH, Strike PW, Wood DE, Swain ID. The effect of combined use of botulinum toxin type A and functional electric stimulation in the treatment of spastic drop foot after stroke: a preliminary investigation. Arch Phys Med Rehabil. 2004;85:902–909.
   PubMed Web of Science ®Google Scholar
• Krach LE. Pharmacotherapy of spasticity: oral medications and intrathecal baclofen. I Child Neurol. 2001;16:31–36.
   PubMed Web of Science ®Google Scholar
• Dvorak EM, Ketchum NC, McGuire JR. The underutilization of intrathecal baclofen in post stroke spasticity. Top Stroke Rehabil. 2011;18: 195–202.
   PubMed Web of Science ®Google Scholar
• Ashworth B. Preliminary trial of carisoprodal in multiple sclerosis. Practitioner 1964;192: 540–542.
   PubMedGoogle Scholar
• Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67:206–207.
   PubMed Web of Science ®Google Scholar
• Gregson JM, Leathley M, Moore AP, Sharma AK, Smith TL, Watkins CL. Reliability of the Tone Assessment Scale and the modified Ashworth scale as clinical tools for assessing post stroke spasticity. Arch Phys Med Rehabil. 1999;80:1013–1016.
   PubMed Web of Science ®Google Scholar
• Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med. 1989;320:1517–1521.
   PubMed Web of Science ®Google Scholar
• Loubster PG, Narayan RK, Sandin KJ, Donovan WH, Russell KD. Continuous infusion of intrathecal baclofen: long-term effects on spasticity and spinal cord injury. Paraplegia. 1991;29:48–64.
   PubMedGoogle Scholar
• Lundstrom E, Smits A, Borg J, Terent A. Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event. Stroke 2010;41:319–324.
   PubMed Web of Science ®Google Scholar
• Moseley AM, Herbert RD, Sherrington C, Maher CG. Evidence for physiotherapy practice: a survey of the Physiotherapy Evidence Database (PEDro). Aust J Physiother 2002;48(1):43–49.
   PubMed Web of Science ®Google Scholar
• Teasell R. Evidence-Based Review of Stroke Rehabilitation. 14th ed. 2012. http://www.ebrsr.com/index.php. Accessed September 12,2012.
   Google Scholar
• Meythaler JM, Guin-Renfroe S, Brunner RC, Hadley MN. Intrathecal baclofen for spastic hypertonia from stroke. Stroke. 2001;32:2099–2109.
   PubMed Web of Science ®Google Scholar
• Meythaler JM, Guin-Renfroe S, Johnson A, Brunner RM. Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch Phys Med Rehabil. 2001;82:1155–1163.
   PubMed Web of Science ®Google Scholar
• Kirazli Y, On AY, Kismali B, Aksit R. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial. Am I Phys Med Rehabil. 1998;77:510–515.
   PubMed Web of Science ®Google Scholar
• Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. I Neurol. 2010;257: 1330–1337.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Mooreb AP, Hardimana O, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport0) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis. 2003;15:289–300.
   PubMed Web of Science ®Google Scholar
• Burbaud P, Wiart L, Dubos IL, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. I Neurol Neurosurg Psychiatry. 1996;61:265–269.
   PubMed Web of Science ®Google Scholar
• Kocabas H, Salli A, Demir AH, Ozerbil OM. Comparison of phenol and alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle for treatment of spastic foot after stroke: a randomized controlled pilot study. Eur I Phys Rehabil Med. 2010;46:5–10.
   PubMed Web of Science ®Google Scholar
• Stamenova P, Koytchev R, Kuhn K, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. Eur I Neurol. 2005;12:453–446.
   PubMed Web of Science ®Google Scholar
• Medici M, Pebet M, Ciblis D. A double-blind, long-term study of tizanidine in spasticity due to cerebrovascular lesions. Curr Med Res Opin. 1989;11:398.
   PubMed Web of Science ®Google Scholar
• Coward DM. Tizaninidine; neuropharmacology and mechanism of action. Neurology. 1994;44: S6–11.
   PubMed Web of Science ®Google Scholar
• Gracies JM, Elovic E, McGuire J, Simpson D. Traditional pharmacological treatments for spasticity part II: general and regional treatments. Muscle Nerve Suppl. 1997;6:92–120.
   Google Scholar
• Gekht AB, Burd GS, Selikhova MV, laish F, Beliakov W. Disorders of muscle tonus and their treatment with sirdalud in patients in the early recovery period of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 1998;98:22–29.
   PubMedGoogle Scholar
• Bes A, Eyssette M, Pierrot-Deseilligny E., Rohmer F., Warter JM.. A multi-centre, double-blind trial of tisanidine a new antispastic agent, in spasticity associated with hemiplegia. Curr Med Res Opin. 1988;10:709–718.
   PubMed Web of Science ®Google Scholar
• Koval'chuk VV, Skoromets AA, Vasileva IV. Comparative efficacy of different muscle relaxants in the rehabilitation of post-stroke patients with spasticity. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108:14-19.
   Google Scholar
• Burns AS, Meythaler JM. Intrathecal baclofen in tetraplegia of spinal origin: efficacy for upper extremity hypertonia. Spinal Cord. 2001;39(8): 413–419.
   PubMed Web of Science ®Google Scholar
• Rekand T, Gronning M. Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. I Rehabil Med. 2011;43:511–514.
   Google Scholar
• Francisco GE, Hu MM, Boake C, Ivanhoe CB. Efficacy of early use of intrathecal baclofen therapy for treating spastic hypertonia due to acquired brain injury. Brain Inj. 2005;19:359–364.
   PubMed Web of Science ®Google Scholar
• Azouvi P, Mane M, Thiebaut JB, Denys P, Remy-Neris O., Bussel B.. Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up. Arch Phys Med Rehabil. 1996;77:35–39.
   PubMed Web of Science ®Google Scholar
• Nance P, Schryvers O, Schmidt B, Dubo H, Loveridge B, Fewer D. Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions. Can I Neurol Sci. 1995;22:22–29.
   Web of Science ®Google Scholar
• Abel NA, Smith RA. Intrathecal baclofen for treatment of intractable spinal spasticity. Arch Phys Med Rehabil. 1994;74:54–58.
   Google Scholar
• Chua KSG, Kong KH. Alcohol neurolysis of the sciatic nerve in the treatment of hemiplegic knee flexor spasticity: clinical outcomes. Arch Phys Med Rehabil. 2000;81:1432–1435.
   PubMed Web of Science ®Google Scholar
• Jang SH, Ahn SH, Park SM, Kim SH, Lee KH, Lee ZI. Alcohol neurolysis of tibial nerve motor branches to the gastrocnemius muscle to treat ankle spasticity in patients with hemiplegic stroke. Arch Phys Med Rehabil. 2004;85:506–508.
   PubMed Web of Science ®Google Scholar
• Childers MK, Stacy M, Cooke D, Stonnington HH. Comparison of two injection techniques using botulinum toxin in spastic hemiplegia. Am I Phys Med Rehabil. 1996;75:462–469.
   PubMed Web of Science ®Google Scholar
• Zuber M, Sebald M, Bathien MD., de Recondo J, Rondot J. Botulinum antibodies in dystonic patients treated with type A botulinum toxin. Neurology. 1993;43:1715–1718.
   PubMed Web of Science ®Google Scholar
• Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C. A randomized, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci. 2005;26:26–31.
   PubMed Web of Science ®Google Scholar
• TeaseII R, Foley N, Pereira S, Sequeira K, Miller T. Evidence to practice: Botulinum toxin in the treatment of spasticity post stroke. Top Stroke Rehabil. 2012;19:115–121.
   PubMed Web of Science ®Google Scholar
• Foley N, Murie-Fernandez M, Speechley M, Salter K, Sequeira K, TeaseII R. Does the treatment of spastic equinovarus deformity following stroke with botulinum toxin increase gait velocity? A systematic review and meta-analysis. Eur I Neurol. 2010;17:1419–1427.
   PubMed Web of Science ®Google Scholar
• Turner-Stokes L, Baguleylb De Graff S, et al. Goal attainment scaling in the evaluation of treatment of upper limb spasticity with botulinum toxin: a secondary analysis from a double-blind placebo controlled randomized clinical trial. I Rehabil Med. 2010;42:81–89.
   Google Scholar